Search

Agalsidase alfa

Agalsidase alfa is a recombinant human α-galactosidase A similar to [agalsidase beta]. … [A220343] Agalsidase alfa was granted EMA approval on 3 August 2001.[L16413]

Avalglucosidase alfa

First developed by Sanofi Genzyme, avalglucosidase alfa is a chemically modified version of [alglucosidase alfa], where synthetic bis-phosphorylated oligosaccharides were attached to the structure to improve … [A232955] Avalglucosidase alfa is a recombinant form of GAA that restores deficient enzyme levels.

Cipaglucosidase alfa

Compared to alglucosidase alfa, cipaglucosidase alfa has a higher M6P content. … [A232955] Other types of enzyme replacement therapy for the treatment of Pompe disease include [alglucosidase alfa] and [avalglucosidase alfa].

Velmanase alfa

[A244509] In February 2023, the FDA also approved velmanase alfa for the same indication.[L45295] Velmanase alfa is currently not approved in Canada. … Velmanase alfa is a recombinant human lysosomal alpha-mannosidase developed for enzyme replacement therapy to treat alpha-mannosidosis.

Andexanet alfa

It also prevents andexanet alfa from taking up space on phospholipid surface membranes, so that native FXa may bind and assemble the prothrominase complex [A35558]. … The procoagulation potential of andexanet alfa is eliminated through the removal of a 34-residue fragment containing Gla: via this truncation, andexanet alfa is unable to bind to membrane surfaces and

Hydrotalcite

Sebelipase alfa

[L39337] Sebelipase alfa is a recombinant form LAL approved for the treatment of LAL deficiency.

Efbemalenograstim alfa

Efbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration … L48852,A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and eventually neutrophils, the administration of recombinant G-CSF like efbemalenograstim alfa

Thrombin alfa

Nevertheless, because the incidence of hemostasis within a timely manner is relatively comparable between the use of thrombin alfa and the placebo treatment in patient subjects, thrombin alfa is not currently … The thrombin alfa product ultimate comes from recombinant human prethrombin-1 [L2079].

Efgartigimod alfa

[A243759,A243784] Efgartigimod alfa is a first-in-class[L39501] antagonist of the neonatal Fc receptor (FcRn) used in the treatment of MG. … Efgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis.